Photo from wikipedia
Key Points Question What is the 2-year safety profile of bimekizumab in patients with moderate to severe plaque psoriasis? Findings In this cohort study including 1789 patients receiving bimekizumab, pooled… Click to show full abstract
Key Points Question What is the 2-year safety profile of bimekizumab in patients with moderate to severe plaque psoriasis? Findings In this cohort study including 1789 patients receiving bimekizumab, pooled data on 2 years of study treatment from 4 phase 2 randomized clinical trials and 4 phase 3 randomized clinical trials identified no safety signals. The incidence of adverse events did not increase with longer duration of exposure to bimekizumab. Meaning These results, pooled to include 2 years of treatment, suggest that bimekizumab is well tolerated among patients with moderate to severe plaque psoriasis.
Journal Title: JAMA Dermatology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!